pyricarbate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2329 1882-26-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pyricarbate
  • anginin
  • anginine
  • angioxine
  • pyridinol carbamate
  • prodectin
A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
  • Molecular weight: 253.26
  • Formula: C11H15N3O4
  • CLOGP: -0.42
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 89.55
  • ALOGS: -2.74
  • ROTB: 6

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.541 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.578 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 38.371 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.427 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 80.760 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 90.780 % High 1
herg hERG pIC50 3.835 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.507 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 2.992 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 76.810 % High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.121 High 1
mh-clint Mouse hepatocyte intrinsic clearance 4.634 High 1
mppb Mouse plasma protein binding (% unbound) 84.300 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 7.112 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 90.320 % High 1
rh-clint Rat hepatocyte intrinsic clearance 5.534 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 97.050 % High 1
rppb Rat plasma protein binding (% unbound) 82.320 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 961.612 uM High 1

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014665 Vasodilator Agents
MeSH PA D053834 Explosive Agents
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D057847 Lipid Regulating Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.25 acidic
pKa2 13.85 acidic
pKa3 4.64 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000166706 NUI
D01396 KEGG_DRUG
C0034257 UMLSCUI
CHEBI:32075 CHEBI
CHEMBL1620144 ChEMBL_ID
4990 PUBCHEM_CID
5011 INN_ID
81R511UV73 UNII
8997 RXNORM
007074 NDDF
D011727 MESH_DESCRIPTOR_UI
D005996 MESH_DESCRIPTOR_UI
81R511UV73 INXIGHT DRUGS

Pharmaceutical products:

None